# Conducting Clinical Trials With Decentralized Elements - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/conducting-clinical-trials-with-decentralized-elements/dc054f22-ff9d-4ea3-8083-fe59c7622408

> FDA guidance document: Conducting Clinical Trials With Decentralized Elements. Issue date: September 18, 2024. Get complete insights and analysis.

---

## Details

- Title: Conducting Clinical Trials With Decentralized Elements
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2024-09-18
- Comment Close Date: 2023-08-01
- Last Changed: 2024-09-18
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2022-D-2870">FDA-2022-D-2870</a>

## Related Documents

- [Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products](https://www.globalkeysolutions.net/guidances/guidance-document/adjusting-for-covariates-in-randomized-clinical-trials-for-drugs-and-biological-products/f58b2adc-b92a-4458-b269-5346d25a8a39)
- [Digital Health Technologies for Remote Data Acquisition in Clinical Investigations](https://www.globalkeysolutions.net/guidances/guidance-document/digital-health-technologies-for-remote-data-acquisition-in-clinical-investigations/d03b5a1b-cf30-4bed-81a8-aa883ea62d4c)
- [Evaluating Cancer Drugs in Patients with Central Nervous System Metastases:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/evaluating-cancer-drugs-in-patients-with-central-nervous-system-metastases-guidance-for-industry/cd630104-b6ee-4993-a2ff-85effca3e866)